Trevi Therapeutics to Raise Up To $74 Million in IPO

Clinical stage biopharmaceutical company, Trevi Therapeutics, updated their filing for an IPO to raise up to $74 million. Trevi is focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. The company intends to trade under the symbol “TRVI.”